Jeff Johnson
Stock Analyst at Baird
(4.65)
# 170
Out of 4,865 analysts
141
Total ratings
58.16%
Success rate
30%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $107 → $97 | $68.76 | +41.07% | 17 | May 30, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $18.43 | +24.80% | 8 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $90.21 | +27.48% | 14 | May 6, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $81.83 | +28.31% | 14 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $20.08 | +19.52% | 16 | May 1, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $84.88 | +27.24% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $18.23 | +9.71% | 1 | Feb 20, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $373.37 | +8.47% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $175.16 | +57.57% | 18 | Oct 24, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $70.16 | +16.88% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $304.39 | -21.81% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $30.88 | +126.68% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $13.37 | +356.25% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $15.37 | +335.91% | 6 | Feb 18, 2022 |
The Cooper Companies
May 30, 2025
Maintains: Outperform
Price Target: $107 → $97
Current: $68.76
Upside: +41.07%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $18.43
Upside: +24.80%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $90.21
Upside: +27.48%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $81.83
Upside: +28.31%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $20.08
Upside: +19.52%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $84.88
Upside: +27.24%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $18.23
Upside: +9.71%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $373.37
Upside: +8.47%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $175.16
Upside: +57.57%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $70.16
Upside: +16.88%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $304.39
Upside: -21.81%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $30.88
Upside: +126.68%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $13.37
Upside: +356.25%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $15.37
Upside: +335.91%